281 related articles for article (PubMed ID: 38262952)
1. Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease.
Thing M; Werge MP; Kimer N; Hetland LE; Rashu EB; Nabilou P; Junker AE; Galsgaard ED; Bendtsen F; Laupsa-Borge J; McCann A; Gluud LL
BMC Gastroenterol; 2024 Jan; 24(1):43. PubMed ID: 38262952
[TBL] [Abstract][Full Text] [Related]
2. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
[TBL] [Abstract][Full Text] [Related]
3. Metabolic alterations of short-chain fatty acids and TCA cycle intermediates in human plasma from patients with gastric cancer.
Kim YL; Lee W; Chung SH; Yu BM; Lee YC; Hong J
Life Sci; 2022 Nov; 309():121010. PubMed ID: 36181864
[TBL] [Abstract][Full Text] [Related]
4. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of short-chain fatty acids in human plasma and serum by GC-MS.
Yao L; Davidson EA; Shaikh MW; Forsyth CB; Prenni JE; Broeckling CD
Anal Bioanal Chem; 2022 Jun; 414(15):4391-4399. PubMed ID: 35091760
[TBL] [Abstract][Full Text] [Related]
6. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
7. Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.
Tews HC; Elger T; Gunawan S; Fererberger T; Sommersberger S; Loibl J; Huss M; Liebisch G; Müller M; Kandulski A; Buechler C
Lipids Health Dis; 2023 Oct; 22(1):164. PubMed ID: 37789460
[TBL] [Abstract][Full Text] [Related]
8. Short-chain fatty acid production in accessible and inaccessible body pools as assessed by novel stable tracer pulse approach is reduced by aging independent of presence of COPD.
Kirschner SK; Ghane P; Park JK; Simbo SY; Ivanov I; Braga-Neto UM; Ten Have GAM; Thaden JJ; Engelen MPKJ; Deutz NEP
Metabolism; 2023 Apr; 141():155399. PubMed ID: 36642114
[TBL] [Abstract][Full Text] [Related]
9. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
[TBL] [Abstract][Full Text] [Related]
10. Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls.
Olsson A; Gustavsen S; Nguyen TD; Nyman M; Langkilde AR; Hansen TH; Sellebjerg F; Oturai AB; Bach Søndergaard H
Front Immunol; 2021; 12():661493. PubMed ID: 34025661
[TBL] [Abstract][Full Text] [Related]
11. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
12. Circulating Short-Chain Fatty Acids and Non-Alcoholic Fatty Liver Disease Severity in Patients with Type 2 Diabetes Mellitus.
Tsai HJ; Hung WC; Hung WW; Lee YJ; Chen YC; Lee CY; Tsai YC; Dai CY
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049552
[TBL] [Abstract][Full Text] [Related]
13. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors.
de la Cuesta-Zuluaga J; Mueller NT; Álvarez-Quintero R; Velásquez-Mejía EP; Sierra JA; Corrales-Agudelo V; Carmona JA; Abad JM; Escobar JS
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30591685
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
[No Abstract] [Full Text] [Related]
15.
Mak AL; Augustijn QJJ; Heymann CJF; Havik S; Verdoes X; Rios-Morales M; Bosmans LA; Verheij J; Meijnikman AS; de Jonge PA; Herrema H; de Vos WM; Nieuwdorp M; Grefhorst A; Holleboom AG
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542455
[TBL] [Abstract][Full Text] [Related]
16. A potential link between plasma short-chain fatty acids, TNF-α level and disease progression in non-alcoholic fatty liver disease: A retrospective study.
Xiong J; Chen X; Zhao Z; Liao Y; Zhou T; Xiang Q
Exp Ther Med; 2022 Sep; 24(3):598. PubMed ID: 35949337
[TBL] [Abstract][Full Text] [Related]
17. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
[TBL] [Abstract][Full Text] [Related]
18. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
19. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
Lai J; Luo L; Zhou T; Feng X; Ye J; Zhong B
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759756
[No Abstract] [Full Text] [Related]
20. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
